Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. April 2018 08:00 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Licensing Agreement with Takeda for the Development and Commercialization of Preclinical Treatment for Prader-Willi Syndrome

-- Oral Ghrelin O-Acyltransferase (GOAT) Inhibitor Complements and Expands Efforts in Prader-Willi Syndrome ---- In Preclinical Models, Prevented Body Weight Gain and Reduced Fat Mass ---- Rhythm...
19. März 2018 16:01 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Presentation of Genetic Epidemiology of LEPR, POMC, And PCSK1 Variants at ENDO 2018

BOSTON, March 19, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic...
12. März 2018 16:01 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

-- Continuing Enrollment in Pivotal Phase 3 Clinical Trial of Setmelanotide in Pro-Opiomelanocortin (POMC) Deficiency Obesity; On Track to Complete Enrollment of 10 Patients in First Half of 2018 ----...
07. März 2018 16:01 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in March

BOSTON, March 07, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic...
04. Januar 2018 08:00 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity

- Final protocol confirmed for pivotal Phase 3 clinical trial in pro-opiomelanocortin (POMC) deficiency obesity - - Setmelanotide granted Orphan Drug Designation for treatment of leptin receptor...
14. November 2017 08:00 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Reports Third Quarter 2017 Financial Results

- Successfully Completed Upsized Initial Public Offering Raising $137.8 Million in Gross Proceeds - - Presented Preliminary Data from Phase 2 Clinical Trial of Setmelanotide in Bardet-Biedl Syndrome...
31. Oktober 2017 08:01 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome

-- Substantial Weight Loss Observed in 4 of 5 Patients -- -- Hunger Scores Improved in All 5 Treated Patients -- -- Results presented at ObesityWeek 2017 Meeting -- BOSTON, Oct. 31, 2017 (GLOBE...
10. Oktober 2017 16:01 ET | Quelle: Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

BOSTON, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of peptide therapeutics for...
04. Oktober 2017 21:08 ET | Quelle: Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering

BOSTON, Oct. 04, 2017 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of peptide therapeutics for treatment of rare...